MedImmune, Genentech Strike Deal In Synagis Case
By Ben James ( May 23, 2008, 12:00 AM EDT) -- Rival biotechnology companies MedImmune Inc. and Genentech Inc. have reached a deal in the patent suit over MedImmune's blockbuster drug Synagis, signaling the end of a dispute that led to the U.S. Supreme Court's January 2007 decision that a patent licensee could challenge a patent's validity without breaching or terminating the licensing agreement....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.